A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly proposed definition of fatty liver disease (FLD) independent of excessive alcohol consumption (EAC) and hepatitis viral infection. Evidence on the mortality risk in different types of FLD [nonalcoholic FLD (NAFLD), alcoholic FLD (AFLD), and MAFLD] is sparse, hindering the identification of high-risk populations for preferential clinical surveillance.

Methods: A total of 11,000 participants in the Third National Health and Nutrition Examination Survey were enrolled.